DC1 is an ADC cytotoxin, similar to the small groove-binding DNAalkylating agent CC-1065. DC1 can be used to synthesize antibody-drug conjugates targeted to the treatment of cancer. DC1Sme is a DC1 derivative with IC50 values of Ramos, Namalwa, HL60 s
DC1 can be used to synthesize antibody-drug conjugates targeted to the treatment of cancer, is an ADC cytotoxin, similar to the small groove-binding DNAalkylating agent CC-1065.
DC10SMe is a DNAalkylating agent that can be used in the synthesis of antibody-drug conjugates (ADC). The IC50 of DC10SMe for Ramos, Namalwa and HL60 s cancer cells were 15 pM, 12 pM and 12 pM, respectively.
DC41 is a derivative of DC1. DC1 is a simplified analogue of CC-1065, an antibody conjugate of cytotoxic DNAalkylating agents, used for targeted treatment of cancer.
The IC50s of DC4SMe on Ramos, Namalwa and HL60 s cancer cells were 1.9 nM, 2.9 nM and 1.8 nM, respectively. DC4SMe can be used for targeted therapy of tumors. DC4SMe is a phosphate prodrug of the cytotoxic DNAalkylating agent DC4 and can be used in the
DGN462 is an effective DNAalkylating agent with anti-tumor activity, as in acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs).
Dimethyl-SGD-1882 (Dimethyl-PBD dimer) is a highly efficient DNAalkylating agent used as an antibody-drug conjugate (ADC) cytotoxin, inhibiting DNA replication.
Duocarmycin GA, an antibody drug conjugate (ADC) toxin and a DNAalkylating agent, effectively targets and binds in the minor groove of DNA. It is particularly potent against multi-drug resistant cell lines, offering a strategic approach in combating resistance.